Fotios S. Fousekis

Dr. Fotios S. Fousekis

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2019 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
FFFotios S. Fousekis
Fotios S. Fousekis
KKKonstantinos H. Katsanos
Konstantinos H. Katsanos
VTVasileios I. Theopistos
Vasileios I. Theopistos
GBGerasimos Baltayiannis
Gerasimos Baltayiannis
MKMaria Kosmidou
Maria Kosmidou
DCDimitrios K Christodoulou
Dimitrios K Christodoulou
Hepatobiliary and pancreatic manifestations have been reported in patients with Crohn’s disease or ulcerative colitis. Our aim was to describe the prevalence of hepatobiliary and pancreatic manifestations in inflammatory bowel disease and their association with the disease itself and the medications used. Data were retrospectively extracted from the clinical records of patients followed up at our tertiary IBD referral Center. Our study included 602 IBD patients, with liver function tests at regular intervals. The mean follow-up was 5.8 years (Std. Dev.: 6.72). Abdominal imaging examinations were present in 220 patients and revealed findings from the liver, biliary tract and pancreas in 55% of examined patients (120/220). The most frequent findings or manifestations from the liver, biliary tract and pancreas were fatty liver (20%, 44/220), cholelithiasis (14.5%, 32/220) and acute pancreatitis (0.6%, 4/602), respectively. There were 7 patients with primary sclerosing cholangitis. Regarding hepatitis viruses, one-third of the patients had been tested for hepatitis B and C. 5% (12/225) of them had positive hepatitis B surface antigen and 13.4% had past infection with hepatitis B virus (positive anti-HBcore). In addition, most of the patients were not immune against hepatitis B (negative anti-HBs), while 3% of patients were anti-HCV positive and only one patient had active hepatitis C. Furthermore, 24 patients had drug-related side effects from the liver and pancreas. The side effects included 21 cases of hepatotoxicity and 3 cases of acute pancreatitis. Moreover, there were two cases of HBV reactivation and one case of chronic hepatitis C, which were successfully treated. In our study, approximately one out of four patients had some kind by a hepatobiliary or pancreatic manifestation. Therefore, it is essential to monitor liver function at regular intervals and differential diagnosis should range from benign diseases and various drug related side effects to severe disorders, such as primary sclerosing cholangitis.

25 August 2018 in Oxford Medical Case Reports
Verified
Journal Article
Open access
PDF file
FFFotios S. Fousekis
Fotios S. Fousekis
PAPanagiota Aggeli
Panagiota Aggeli
SGSpyridon Gkogkos
Spyridon Gkogkos
PCPanagiota Christou
Panagiota Christou
GPGeorgios Pappas-Gogos
Georgios Pappas-Gogos
Rectal ischemia rarely occurs because of the rich vascular supply of the rectum, while endoscopic presentation of ischemic colitis always is not distinct and can uncommonly mimic malignant neoplasm. We present a case of a rectal ischemia, which presented with haematochezia and proctoscopy revealed a large ulcerating mass, masquerading as rectal cancer and obstructed the lumen of rectum. However, histological examinations showed only features for ischemic colitis and no evidence for malignancy. The patient was treated conservatively and 10 days later, new endoscopy showed complete disappearance of ulcerated mass, and new biopsies confirmed the initial diagnosis. Awareness and early diagnosis of ‘mass forming’ entity of ischemic colitis is very essential in order to carry out appropriate treatment and avoid severe complications.

1 April 2020 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
FFFotios S. Fousekis
Fotios S. Fousekis
AKAndreas Katsanos
Andreas Katsanos
KKKonstantinos H. Katsanos
Konstantinos H. Katsanos
DCDimitrios K Christodoulou
Dimitrios K Christodoulou

3 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FFFotios S. Fousekis
Fotios S. Fousekis
KMKonstantinos Mpakogiannis
Konstantinos Mpakogiannis
Georgios D. LianosGeorgios D. Lianos
Georgios D. Lianos
EAElisabetta Antonelli
Elisabetta Antonelli
GBGabrio Bassotti
Gabrio Bassotti
KKKonstantinos H. Katsanos
Konstantinos H. Katsanos
Primary sclerosing cholangitis (PSC) is a chronic, immune-mediated cholestatic liver disease characterized by progressive bile duct inflammation and fibrosis. Its strong association with inflammatory bowel disease (IBD) highlights the possible role of the gut–liver axis in disease pathogenesis. Here, we review the mechanisms that may contribute to the disruption of the gut–liver axis, leading to liver injury and the development of PSC. In particular, disruption of the intestinal barrier allows microbial products to enter the portal circulation, stimulating hepatic immune cells and triggering biliary inflammation. Concurrently, gut-primed lymphocytes expressing mucosal homing receptors migrate aberrantly to the liver, where they may contribute to biliary epithelial cell injury. Dysbiosis, characterized by reduced microbial diversity and the expansion of bile-tolerant and pro-inflammatory taxa, amplifies this immune activation and disturbs gut–liver homeostasis. Moreover, bile acids act as signaling molecules, regulating metabolism and immune responses through receptors such as FXR and TGR5. Dysregulation of these pathways may promote cholestasis, inflammation, and fibrosis. By understanding these interactions, we may identify novel therapeutic targets for PSC.

20 December 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BFBernadett Farkas
Bernadett Farkas
TBTalat Bessissow
Talat Bessissow
JLJimmy K. Limdi
Jimmy K. Limdi
KSKarishma Sethi-Arora
Karishma Sethi-Arora
AKAnna Kagramanova
Anna Kagramanova
TMTamás Molnár
Tamás Molnár
Background/Objectives: Data on the real-world effectiveness and safety of selective JAK inhibitors (JAKis) in ulcerative colitis (UC) and Crohn’s disease (CD) are limited. Methods: We conducted a multicentre, retrospective study to assess clinical, biochemical, and endoscopic outcomes of selective JAKis in bio-experienced UC and CD. Results: A total of 246 patients (mean age: 40.5 ± 14.5 years; 131 UC and 115 CD) were included with a median follow-up of 7.5 months. Among the CD patients receiving upadacitinib (n = 115), 76.2% achieved clinical remission (CR) at week 12. Furthermore, 59.5% of the upadacitinib-treated UC patients (n = 100) experienced CR at week 8. Corticosteroid-free CR (CSFCR) was achieved by 76.9% of the CD patients and 80.6% of the UC patients at week 24, while 50.0% and 36.1% experienced endoscopic remission. At week 52, 66.7% of the CD and 86.2% of the UC patients achieved CSFCR, whereas 54.5% and 52.9% had endoscopic remission. In UC, the effectiveness of upadacitinib was not compromised by prior tofacitinib failure, while the upadacitinib-treated CD patients with stricturing and penetrating disease were less likely to achieve CR by the end of the induction phase (p = 0.04). C-reactive protein (p[CD] < 0.0001; p[UC] < 0.0001) and faecal calprotectin (p[CD] < 0.0001; p[UC] = 0.02) decreased significantly in both patient groups as early as week 2. Among the filgotinib-treated UC patients (n = 31), 28.6% were in CR at week 12. At week 24 and 52, 59.1% and 60% achieved CSFCR, while 0.0% and 20.0% had endoscopic remission. Both C-reactive protein (p = 0.04) and faecal calprotectin (p = 0.04) decreased significantly by week 12. Hyperlipidaemia (9.7–9.8%) was the most common adverse event. Conclusions: Selective JAKis are rapidly effective and safe for treating refractory, moderate-to-severe CD and UC.

18 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
GPGeorgios Pappas-Gogos
Georgios Pappas-Gogos
KTKostas Tepelenis
Kostas Tepelenis
FFFotios S. Fousekis
Fotios S. Fousekis
KKKonstantinos H. Katsanos
Konstantinos H. Katsanos
MPMichail Pitiakoudis
Michail Pitiakoudis
KVKonstantinos Vlachos
Konstantinos Vlachos
Gastric cancer (GC) is one of the most common and deadly malignancies worldwide. Helicobacter pylori have been documented as a risk factor for GC. The development of sequencing technology has broadened the knowledge of the gastric microbiome, which is essential in maintaining homeostasis. Recent studies have demonstrated the involvement of the gastric microbiome in the development of GC. Therefore, the elucidation of the mechanism by which the gastric microbiome contributes to the development and progression of GC may improve GC’s prevention, diagnosis, and treatment. In this review, we discuss the current knowledge about changes in gastric microbial composition in GC patients, their role in carcinogenesis, the possible therapeutic role of the gastric microbiome, and its implications for current GC therapy.